Pharmacotherapy

On this page

Pharmacotherapy (Anorexia Nervosa) - Thin Ice Tactics

  • No FDA-approved drugs for core AN symptoms; primarily treat comorbidities.
  • SSRIs (e.g., Fluoxetine):
    • For comorbid depression/anxiety, after some weight restoration.
    • ⚠️ Caution if severely underweight: cardiac risks, potential weight ↓.
  • Atypical Antipsychotics (e.g., Olanzapine):
    • Off-label use for modest weight gain (e.g., 2.5-5 mg/day).
    • May ↓ anxiety, obsessionality.

⭐ Olanzapine may be used off-label in Anorexia Nervosa for promoting weight gain and reducing anxiety or obsessional thoughts, though no medication is FDA-approved for core AN symptoms.

Pharmacotherapy (Bulimia Nervosa) - Binge Halt!

  • SSRIs: First-line treatment.
    • Fluoxetine: Only FDA-approved drug.
      • Dose: 60 mg/day (higher than for depression).
      • Mechanism: Reduces binge-purge frequency.
    • Other SSRIs (e.g., sertraline, citalopram, escitalopram): May be used off-label.
  • Topiramate:
    • Reduces bingeing and purging episodes.
    • Associated with weight loss.
    • ⚠️ Side effects: Cognitive (e.g., word-finding difficulties, paresthesias).
  • Contraindicated Medications:
    • Bupropion: ⚠️ Contraindicated due to ↑ seizure risk in patients who purge.
  • Limited Role:
    • TCAs & MAOIs: Generally not preferred due to side effects and dietary restrictions (MAOIs).

⭐ Fluoxetine is the only FDA-approved medication for Bulimia Nervosa, typically at a higher dose (60 mg/day) than used for depression.

Pharmacotherapy (Binge Eating Disorder) - Feast Control

  • SSRIs (e.g., Fluoxetine, Sertraline):
    • Moderate efficacy in ↓ binge frequency.
    • Addresses comorbid depression/anxiety.
    • Often first-line due to tolerability.
  • Lisdexamfetamine (Vyvanse):
    • Stimulant, prodrug of dextroamphetamine.
    • Reduces binge days/episodes.
    • Monitor for cardiovascular & psychiatric side effects.

    ⭐ Lisdexamfetamine (Vyvanse) is FDA-approved for treating moderate to severe Binge Eating Disorder in adults and can reduce binge frequency.

  • Anticonvulsants:
    • Topiramate: ↓ binge frequency, promotes weight loss. Side effects: cognitive (e.g., word-finding difficulty), paresthesias. ⚠️ Risk of kidney stones, metabolic acidosis.
    • Zonisamide: Similar to topiramate; less studied for BED.
  • Naltrexone/Bupropion Combination:
    • May be considered, especially with co-occurring obesity.
    • Naltrexone (opioid antagonist) + Bupropion (NDRI).

Pharmacotherapy (Key Drugs Summary) - Pills & Alerts

DrugIndicationBenefit(s)Key SEs / ⚠️ Cautions
FluoxetineBN↓ binge/purgeInsomnia, GI / QTc risk (malnourished), Serotonin Syn.
OlanzapineAN (wt gain)↑ weight, ↓ anxietySedation, metabolic syn. / QTc risk
LisdexamfetamineBED↓ bingesInsomnia, dry mouth / Cardiac risk, abuse
TopiramateBED/BN (off-label)↓ binge, wt. lossParesthesia, cognitive slow / Stones, acidosis, teratogenic

⭐ Bupropion is contraindicated in patients with a current or prior diagnosis of Bulimia Nervosa or Anorexia Nervosa due to an increased risk of seizures.

High‑Yield Points - ⚡ Biggest Takeaways

  • SSRIs (Fluoxetine) are first-line for Bulimia Nervosa (BN) & Binge Eating Disorder (BED).
  • Fluoxetine (60mg) is FDA-approved for BN; higher dose than depression.
  • Limited drug role in Anorexia Nervosa (AN) for weight gain; treat comorbidities.
  • Olanzapine may aid weight gain in AN (off-label).
  • Lisdexamfetamine is FDA-approved for moderate-severe BED.
  • Avoid Bupropion in BN/AN (↑ seizure risk).
  • Topiramate (off-label for BN/BED) can cause weight loss; monitor cognition_._

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Pharmacotherapy

  1. 1. Which of the following statements is NOT true regarding electroconvulsive therapy (ECT)?

    • A. Primary use in major depression
    • B. Absence of absolute contraindications
    • C. Contraindication during pregnancy
    • D. Relative contraindication in pheochromocytoma
    Show answer

    Answer: C. Contraindication during pregnancy

    Contraindication during pregnancy - ECT can be used during pregnancy for severe depression, mania, or psychosis, especially when rapid treatment is required or medication presents greater fetal risk. - With appropriate fetal monitoring and positioning, ECT is considered a treatment option for psychiatric emergencies in pregnancy; therefore, it should not categorically be avoided. Primary use in major depression - Major depressive disorder is the principal indication for ECT, particularly when depression is severe, psychotic, treatment-resistant, or associated with high suicide risk. - This statement is true because ECT provides a rapid and effective response in severe depression, often when medication is inadequate or too slow. Absence of absolute contraindications - ECT has no absolute contraindications; even substantial medical risks may be managed with specialist assessment, intensive monitoring, and appropriate precautions. - Conditions such as recent myocardial infarction or raised intracranial pressure are relative risks, not absolute exclusions, when psychiatric urgency justifies treatment. Relative contraindication in pheochromocytoma - Pheochromocytoma is a relative contraindication because the catecholamine surge associated with ECT may precipitate a dangerous hypertensive crisis. - It is not an absolute contraindication: careful pre-treatment evaluation, blood-pressure control, and monitoring may permit ECT when the psychiatric indication is compelling.

  2. 2. Antidepressant drug used in nocturnal enuresis is:

    • A. Sertraline
    • B. Fluoxetine
    • C. Trazodone
    • D. Imipramine
    Show answer

    Answer: D. Imipramine

    Imipramine - Imipramine is a tricyclic antidepressant with an established indication for childhood nocturnal enuresis. - Its anticholinergic effects may relax the detrusor and increase bladder capacity, while central effects may promote arousal from sleep. Sertraline - Sertraline is a selective serotonin reuptake inhibitor (SSRI) used mainly for depression, anxiety disorders, and panic disorder. - It is not an established treatment for nocturnal enuresis and lacks imipramine’s relevant bladder-relaxing and arousal-modulating effects. Fluoxetine - Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) primarily used for depression, anxiety disorders, and obsessive-compulsive disorder. - It is not indicated for nocturnal enuresis and does not provide imipramine’s specific bladder-relaxing or arousal-modulating benefits. Trazodone - Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) commonly used for depression and insomnia because of its sedative effects. - It is not used for nocturnal enuresis, and its mechanism does not provide the established benefits for bladder control associated with imipramine.

  3. 3. Which feature is NOT characteristic of anorexia nervosa?

    • A. Decreased appetite
    • B. Body image distortion
    • C. Vigor despite illness
    • D. Significant weight loss
    Show answer

    Answer: A. Decreased appetite

    Decreased appetite - Appetite is often preserved early despite deliberate food restriction; reduced appetite can develop during prolonged starvation. - Decreased appetite is therefore not the characteristic basis of anorexia nervosa, unlike weight loss, body image distortion, and apparent vigor despite illness. Significant weight loss - Significant weight loss or failure to gain expected weight is characteristic of anorexia nervosa and commonly results from restriction, excessive exercise, or purging. - This option is not false because significant weight loss reflects the disorder’s persistent energy restriction and pursuit of thinness. Vigor despite illness - Patients may show surprising energy and hyperactivity despite severe malnutrition and physical debilitation, sometimes to burn calories or suppress hunger. - This option is not false because apparent vigor despite illness can occur even when the patient’s medical condition is deteriorating. Body image distortion - Body image distortion is a core feature, with individuals perceiving themselves as overweight or fearing weight gain despite being severely underweight. - This option is not false because distorted body perception drives the persistent pursuit of thinness and restrictive behaviors characteristic of anorexia nervosa.

  4. 4. Which one of the following medications is used to aid in smoking cessation?

    • A. Naltrexone
    • B. Fluoxetine
    • C. Buspirone
    • D. Bupropion
    Show answer

    Answer: D. Bupropion

    Bupropion - Bupropion sustained-release is an FDA-approved, first-line non-nicotine medication for smoking cessation that reduces withdrawal symptoms and the urge to smoke. - By inhibiting dopamine and norepinephrine reuptake, it partly reproduces nicotine's reward pathway; treatment commonly begins 1–2 weeks before quitting. Naltrexone - Naltrexone is an opioid antagonist used mainly to reduce cravings in alcohol dependence and prevent relapse in opioid use disorder. - It is not a standard pharmacotherapy for nicotine withdrawal or smoking cessation, unlike bupropion and varenicline. Fluoxetine - Fluoxetine is an SSRI used for depression, obsessive-compulsive disorder, and bulimia, rather than as a nicotine-dependence treatment. - Although depression may coexist with smoking, SSRIs do not reliably reduce nicotine withdrawal or constitute standard smoking-cessation therapy. Buspirone - Buspirone is a 5-HT1A partial agonist used primarily as an anxiolytic for generalized anxiety disorder. - It has no established efficacy in smoking cessation, so it does not address nicotine withdrawal as bupropion does.

  5. 5. All of the following are features of morphine withdrawal EXCEPT:

    • A. Yawning
    • B. Lacrimation
    • C. Mydriasis
    • D. Hypotension
    Show answer

    Answer: D. Hypotension

    Hypotension - Hypotension is not typical of morphine withdrawal; sympathetic overactivity more commonly produces hypertension and other signs of autonomic hyperactivity. - Therefore, hypotension is the exception among these choices, whereas withdrawal is characterized by increased sympathetic nervous system activity. Yawning - Yawning is a common early symptom of morphine withdrawal, often occurring with fatigue and restlessness as opioid dependence is interrupted. - It reflects autonomic dysregulation and increased sympathetic activity during withdrawal, so it is consistent with the expected withdrawal syndrome rather than the exception. Lacrimation - Lacrimation, or excessive tearing, is a prominent autonomic manifestation of morphine withdrawal and commonly accompanies rhinorrhea. - Together, lacrimation and rhinorrhea contribute to the flu-like appearance of opioid withdrawal, making this option a recognized withdrawal symptom. Mydriasis - Mydriasis, or dilated pupils, is a classic sign of morphine withdrawal caused by reduced parasympathetic influence and increased sympathetic activity. - This distinguishes withdrawal from opioid intoxication, which characteristically produces miosis or pinpoint pupils, so mydriasis fits the withdrawal syndrome.

  6. 6. Which laboratory change is NOT expected from recurrent self-induced vomiting in anorexia nervosa, without diarrhoea or laxative use?

    • A. Hyperamylasemia
    • B. Metabolic alkalosis
    • C. Hypokalemia
    • D. Hyperchloremia
    Show answer

    Answer: D. Hyperchloremia

    Hyperchloremia is the exception because recurrent vomiting typically causes chloride depletion and hypochloremic metabolic alkalosis. Hyperamylasemia can occur through increased salivary isoamylase associated with recurrent vomiting. Metabolic alkalosis follows loss of gastric acid and is maintained by volume and chloride depletion. Hypokalemia results from potassium depletion and increased renal potassium loss associated with secondary aldosterone activity.

  7. 7. What is the best choice of antianxiety agent for a 40-year-old woman with generalized anxiety disorder and a history of benzodiazepine abuse?

    • A. buspirone
    • B. flurazepam
    • C. clonazepam
    • D. zolpidem
    Show answer

    Answer: A. buspirone

    buspirone - Buspirone is a 5-HT1A partial agonist effective for long-term generalized anxiety disorder treatment without the abuse, tolerance, and withdrawal risks associated with benzodiazepines. - Its non-sedating, non-addictive profile makes it particularly suitable for a patient with prior benzodiazepine abuse, although therapeutic benefit typically takes 2–4 weeks to develop. flurazepam - Flurazepam is a long-acting benzodiazepine primarily used as a hypnotic rather than for chronic generalized anxiety disorder management. - Its substantial dependence and withdrawal potential makes it inappropriate in someone with a history of benzodiazepine abuse, despite possible short-term anxiolytic effects. clonazepam - Clonazepam can treat generalized anxiety disorder and panic disorder, but it is still a benzodiazepine with clinically important abuse potential. - A history of benzodiazepine abuse makes relapse, tolerance, and physiological dependence major concerns, so a non-benzodiazepine option is preferred for ongoing treatment. zolpidem - Zolpidem is a non-benzodiazepine sedative-hypnotic primarily indicated for insomnia, not as established long-term therapy for generalized anxiety disorder. - Although structurally distinct from benzodiazepines, it retains misuse and dependence potential, making it unsuitable for this patient and not an appropriate treatment for chronic GAD.

  8. 8. Which anxiolytic acts through 5-HT1A receptor partial agonism without exhibiting significant anticonvulsant or muscle relaxant properties?

    • A. Zolpidem
    • B. Phenobarbital
    • C. Diazepam
    • D. Buspirone
    Show answer

    Answer: D. Buspirone

    Buspirone - Buspirone is a distinctive anxiolytic that acts primarily as a partial agonist at 5-HT1A receptors, directly matching the mechanism described. - Unlike benzodiazepines, it lacks significant anticonvulsant and muscle relaxant properties, with minimal sedative-hypnotic effects and no typical physical dependence or withdrawal. Zolpidem - Zolpidem is a non-benzodiazepine hypnotic that selectively acts at GABA-A receptors, producing predominantly sedative effects rather than anxiolysis through 5-HT1A receptors. - Its primary use is insomnia, and it does not exhibit the characteristic 5-HT1A partial agonism of buspirone or serve as the expected anxiolytic in this question. Phenobarbital - Phenobarbital is a barbiturate that prolongs GABA-A chloride-channel opening, producing strong sedative, hypnotic, and anticonvulsant effects. - Its mechanism is distinct from 5-HT1A partial agonism, and its substantial anticonvulsant and dependence-related effects make it unsuitable for the described profile. Diazepam - Diazepam is a benzodiazepine that enhances GABA-A receptor activity, producing anxiolytic, sedative, muscle relaxant, and anticonvulsant effects. - It does not primarily act through 5-HT1A partial agonism, and its prominent muscle-relaxant and anticonvulsant actions contradict the features described in the question.

  9. 9. Bulimia nervosa with recurrent self-induced vomiting is most characteristically associated with which finding?

    • A. Metabolic acidosis
    • B. Respiratory acidosis
    • C. Metabolic alkalosis
    • D. Respiratory alkalosis
    Show answer

    Answer: C. Metabolic alkalosis

    Metabolic alkalosis results from loss of gastric hydrochloric acid during recurrent vomiting. Respiratory alkalosis is caused by primary hyperventilation, not gastric acid loss. Respiratory acidosis is caused by primary alveolar hypoventilation; compensatory hypoventilation here is secondary to metabolic alkalosis. Metabolic acidosis can follow diarrhoeal bicarbonate loss but is not the characteristic result of the specified gastric losses.

  10. 10. According to DSM-5-TR, all are diagnostic criteria for anorexia nervosa EXCEPT:

    • A. Disturbed body image
    • B. Significantly low body weight
    • C. Intense fear of weight gain
    • D. Amenorrhea for 3 months
    Show answer

    Answer: D. Amenorrhea for 3 months

    Amenorrhea for 3 months is not a DSM-5-TR diagnostic requirement for anorexia nervosa, although it may occur because of nutritional and hypothalamic dysfunction. Disturbed body image is part of the diagnostic framework. Significantly low body weight resulting from restricted energy intake is a diagnostic criterion. Intense fear of weight gain, or persistent behavior interfering with weight gain, is also part of the diagnostic framework.

Flashcards: Pharmacotherapy

  1. 1. For diagnosing bulimia nervosa, binge eating and inappropriate compensatory behaviors both should occur, at least _____ a week for _____ months.

    Show answer

    once · 3

  2. 2. is the most common eating disorder.

    Show answer

    Binge eating disorder

  3. 3. Which eating disorder is characterised by excessive exercise?

    Show answer

    Anorexia nervosa

  4. 4. Anorexia nervosa is separated into _____ and _____ subtypes

    Show answer

    restricting · binge/purge

  5. 5. _____ is defined as excessive dieting, exercise, or binge eating/purging with BMI _____ kg/m2

    Show answer

    Anorexia nervosa · < 18.5

  6. 6. Anorexia nervosa is associated with _____ bone density and _____ stress fractures

    Show answer

    decreased · metatarsal

  7. 7. Patients with anorexia nervosa present with _____cardia, _____tension, and decreased bowel sounds

    Show answer

    brady · hypo

  8. 8. Bulimia nervosa is associated with _____ and _____ erosion due to excessive vomiting

    Show answer

    parotitis · enamel

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF